Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price Target

Benzinga · 1d ago
Guggenheim analyst Yatin Suneja reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $60 price target.